Analysis of Genotype 1b Hepatitis C Virus IRES in Serum and Peripheral Blood Mononuclear Cells in Patients Treated with Interferon and Ribavirin

Table 2

Distribution of mutations developing in the 5′untranslated region of HCV in serum and PBMC from patients treated with pegylated interferon and ribavirin.

Position	Mutation	Domain	Number of patients		Number of variants
			SVR+	SVR−	PBMC	Serum
104	U-C	IIb		1	1
104*	C-U	IIb	1			1
107*	G-A	IIb		1		1
109	A-C	IIb		1	1
119	A-U			2	1	1
121	C-U			1		1
142	A-G	IIIa		1	1
146	G del	IIIa		1	1
183	C-U	IIIb	1	3	4	1
183*	C-U	IIIb	1		1
188	G-U	IIIb		1	1
206	A ins	IIIb		1	1
233*	A-G	IIIb	1		1
243	A-G	IIIc		1	1
243*	G-A	IIIc		1	1	1
244	A-G	IIIc		1	1
261	G-U	IIId		1	1
263	U-G	IIId		1	1	1
271	G-U; U-G	IIId		2	2	1
273	U-G	IIId		1	1	1
274	C-A	IIId		1	1	1
277	U-G	IIId		1	1	1

SVR+, sustained virological response; SVR−, no sustained virological response; PBMC, peripheral blood mononuclear cell.
*Mutations were detected after the end of therapy (weeks 60 and 72).